{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:21:51Z","timestamp":1794255711967,"version":"4.9.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ymgme.2026.110291","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:11:00Z","timestamp":1791389460000},"page":"110291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A prospective, longitudinal, natural history study of neurological disease trajectory in children with late-infantile or juvenile-onset GM1 gangliosidosis or GM2 gangliosidoses: the PRONTO study"],"prefix":"10.1016","volume":"149","author":[{"given":"Laura","family":"L\u00f3pez de Frutos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Dhamija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"H\u00e9ron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Fay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne A.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Bourchany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Cirnigliaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lia","family":"Hoebeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Almeida","family":"do Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ardissone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyros","family":"Batzios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Freitag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2026.110291_bb0005","first-page":"663","article-title":"The GM1 and GM2 gangliosidoses: natural history and progress toward therapy","volume":"13","author":"Regier","year":"2016","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"10.1016\/j.ymgme.2026.110291_bb0010","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2147\/TACG.S206076","article-title":"GM1 gangliosidosis: mechanisms and management","volume":"14","author":"Rha","year":"2021","journal-title":"Appl. Clin. Genet."},{"key":"10.1016\/j.ymgme.2026.110291_bb0015","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2174\/1566523218666180404162622","article-title":"Genetics and therapies for GM2 gangliosidosis","volume":"18","author":"Cachon-Gonzalez","year":"2018","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ymgme.2026.110291_bb0020","first-page":"1","article-title":"Lysosomal storage diseases","volume":"2","author":"Ferreira","year":"2017","journal-title":"Transl. Sci. Rare Dis."},{"key":"10.1016\/j.ymgme.2026.110291_bb0025","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ymgme.2008.04.012","article-title":"GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects","volume":"94","author":"Brunetti-Pierri","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.110291_bb0030","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.3390\/ijms21176213","article-title":"GM2 gangliosidoses: clinical features, pathophysiological aspects, and current therapies","volume":"21","author":"Leal","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2026.110291_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.734878","article-title":"GM1 gangliosidosis-a mini-review","volume":"12","author":"Nicoli","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.ymgme.2026.110291_bb0040","first-page":"23","article-title":"Morquio-like dysostosis multiplex presenting with neuronopathic features is a distinct GLB1-related phenotype","volume":"60","author":"Stockler-Ipsiroglu","year":"2021","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2026.110291_bb0045","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/21678707.2016.1266933","article-title":"Galactosialidosis: historic aspects and overview of investigated and emerging treatment options","volume":"5","author":"Annunziata","year":"2017","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.ymgme.2026.110291_bb0050","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/08830738060210061101","article-title":"Diagnosis and molecular characterization of non-classic forms of Tay-Sachs disease in Brazil","volume":"21","author":"Rozenberg","year":"2006","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.ymgme.2026.110291_bb0055","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0925-4439(99)00074-5","article-title":"Biochemical consequences of mutations causing the GM2 gangliosidoses","volume":"1455","author":"Mahuran","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2026.110291_bb0060","author":"Orphanet"},{"key":"10.1016\/j.ymgme.2026.110291_bb0065","author":"Orphanet"},{"key":"10.1016\/j.ymgme.2026.110291_bb0070","author":"Orphanet"},{"key":"10.1016\/j.ymgme.2026.110291_bb0075","article-title":"Genotype-phenotype correlation of gangliosidosis mutations using in silico tools and homology modeling","volume":"20","author":"Ou","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2026.110291_bb0080","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ymgme.2017.04.011","article-title":"Infantile gangliosidoses: mapping a timeline of clinical changes","volume":"121","author":"Jarnes Utz","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.110291_bb0085","article-title":"The juvenile gangliosidoses: a timeline of clinical change","volume":"25","author":"King","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2026.110291_bb0090","first-page":"88","article-title":"Progressive dystonia as a presenting manifestation of GM1 gangliosidosis","volume":"1","author":"Mehta","year":"2019","journal-title":"Clin. Park. Relat. Disord."},{"key":"10.1016\/j.ymgme.2026.110291_bb0095","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70176","article-title":"Evaluation of the landscape of pharmacodynamic biomarkers in GM1 and GM2 gangliosidosis","volume":"18","author":"Stern","year":"2025","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ymgme.2026.110291_bb0100","doi-asserted-by":"crossref","first-page":"e1550","DOI":"10.1542\/peds.2006-0588","article-title":"The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported","volume":"118","author":"Maegawa","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2026.110291_bb0105","doi-asserted-by":"crossref","first-page":"e1233","DOI":"10.1542\/peds.2011-0078","article-title":"Natural history of infantile G(M2) gangliosidosis","volume":"128","author":"Bley","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2026.110291_bb0110","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1469-8749.2011.04160.x","article-title":"GM2 gangliosidosis in a UK study of children with progressive neurodegeneration: 73 cases reviewed","volume":"54","author":"Smith","year":"2012","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ymgme.2026.110291_bb0115","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ymgme.2019.12.012","article-title":"The natural history of type 1 infantile GM1 gangliosidosis: a literature-based meta-analysis","volume":"129","author":"Lang","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.110291_bb0120","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1016\/j.gim.2022.09.001","article-title":"Quantitative longitudinal natural history of 8 gangliosidoses-conceptual framework and baseline data of the German 8-in-1 disease registry. A cross-sectional analysis","volume":"24","author":"Ries","year":"2022","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2026.110291_bb0125","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1186\/s13023-024-03409-1","article-title":"A natural history study of pediatric patients with early onset of GM1 gangliosidosis, GM2 gangliosidoses, or Gaucher disease type 2 (RETRIEVE)","volume":"19","author":"H\u00e9ron","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2026.110291_bb0130","article-title":"GM1 gangliosidosis type II: results of a 10-year prospective study","volume":"26","author":"D'Souza","year":"2024","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2026.110291_bb0135","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1212\/01.wnl.0000219042.60538.92","article-title":"Scale for the assessment and rating of ataxia: development of a new clinical scale","volume":"66","author":"Schmitz-H\u00fcbsch","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2026.110291_bb0140","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/mds.29255","article-title":"Temporal dynamics of the scale for the assessment and rating of ataxia in spinocerebellar ataxias","volume":"38","author":"Moulaire","year":"2023","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymgme.2026.110291_bb0145","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1007\/s12311-024-01700-2","article-title":"Content validity of the modified functional scale for the assessment and rating of ataxia (f-SARA) instrument in spinocerebellar ataxia","volume":"23","author":"Potashman","year":"2024","journal-title":"Cerebellum"},{"key":"10.1016\/j.ymgme.2026.110291_bb0150","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s12311-012-0421-3","article-title":"Inventory of non-ataxia signs (INAS): validation of a new clinical assessment instrument","volume":"12","author":"Jacobi","year":"2013","journal-title":"Cerebellum"},{"key":"10.1016\/j.ymgme.2026.110291_bb0155","article-title":"Efficacy results from a 12-month double-blind randomized trial of arimoclomol for treatment of Niemann-Pick disease type C (NPC): presenting a rescored 4-domain NPC Clinical Severity Scale","volume":"43","author":"Mengel","year":"2025","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2026.110291_bb0160","series-title":"Vineland-3: Vineland Adaptive Behavior Scales","author":"Sparrow","year":"2016"},{"key":"10.1016\/j.ymgme.2026.110291_bb0165","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12913-018-3047-4","article-title":"Screening for caregivers at risk: extended validation of the short version of the Burden Scale for Family Caregivers (BSFC-s) with a valid classification system for caregivers caring for an older person at home","volume":"18","author":"Pendergrass","year":"2018","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.ymgme.2026.110291_bb0170","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1471-2318-14-23","article-title":"Subjective caregiver burden: validity of the 10-item short version of the Burden Scale for Family Caregivers BSFC-s","volume":"14","author":"Graessel","year":"2014","journal-title":"BMC Geriatr."},{"key":"10.1016\/j.ymgme.2026.110291_bb0175","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4274\/balkanmedj.galenos.2022.2022-3-75","article-title":"Single institutional experience with GM1 gangliosidosis: clinical and laboratory results of 14 patients","volume":"39","author":"Akar","year":"2022","journal-title":"Balkan Med. J."},{"key":"10.1016\/j.ymgme.2026.110291_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2026.1839278","article-title":"Identification of novel compound heterozygous mutations in the GLB1 gene by whole-exome sequencing in a case of infantile GM1 gangliosidosis: a case report","volume":"14","author":"Zhong","year":"2026","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.ymgme.2026.110291_bb0185","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/humu.9363","article-title":"Molecular analysis of the HEXA gene in Italian patients with infantile and late onset Tay-Sachs disease: detection of fourteen novel alleles","volume":"26","author":"Montalvo","year":"2005","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2026.110291_bb0190","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1590\/1678-4685-gmb-2016-0268","article-title":"Relative frequency and estimated minimal frequency of lysosomal storage diseases in Brazil: report from a reference laboratory","volume":"40","author":"Giugliani","year":"2017","journal-title":"Genet. Mol. Biol."},{"key":"10.1016\/j.ymgme.2026.110291_bb0195","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13023-020-01354-3","article-title":"Patient and caregiver perspectives on burden of disease manifestations in late-onset Tay-Sachs and Sandhoff diseases","volume":"15","author":"Lyn","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2026.110291_bb0200","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ajmg.a.63038","article-title":"GM1-gangliosidosis: the caregivers' assessments of symptom impact and most important symptoms to treat","volume":"191","author":"Bingaman","year":"2023","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgme.2026.110291_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1392683","article-title":"Therapeutic developments for neurodegenerative GM1 gangliosidosis","volume":"18","author":"Foster","year":"2024","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ymgme.2026.110291_bb0210","author":"European Medicines Agency"},{"key":"10.1016\/j.ymgme.2026.110291_bb0215","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1111\/ene.15871","article-title":"Efficacy and safety of miglustat in the treatment of GM2 gangliosidosis: a systematic review","volume":"30","author":"Mansouri","year":"2023","journal-title":"Eur. J. Neurol."},{"issue":"Suppl. 3","key":"10.1016\/j.ymgme.2026.110291_bb0220","doi-asserted-by":"crossref","first-page":"S355","DOI":"10.1007\/s10545-010-9186-3","article-title":"Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type Sandhoff: results of a 3-year follow-up","volume":"33","author":"Masciullo","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2026.110291_bb0225","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.1371","article-title":"Substrate reduction therapy with miglustat in pediatric patients with GM1 type 2 gangliosidosis delays neurological involvement: a multicenter experience","volume":"8","author":"Fischetto","year":"2020","journal-title":"Mol. Genet. Genomic Med."},{"key":"10.1016\/j.ymgme.2026.110291_bb0230","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13023-018-0844-0","article-title":"Miglustat in Niemann-Pick disease type C patients: a review","volume":"13","author":"Pineda","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2026.110291_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.108113","article-title":"First-in-human single-dose study of nizubaglustat, a dual inhibitor of ceramide glucosyltransferase and non-lysosomal glucosylceramidase: safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending and multiple doses in healthy adults","volume":"141","author":"Paquet Luzy","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.110291_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2026.110164","article-title":"The RAINBOW study: a phase 2 trial evaluating the 3-month pharmacokinetic and pharmacodynamic data and 18-month clinical and safety outcomes of nizubaglustat in GM2 gangliosidoses or Niemann-Pick type C disease","volume":"148","author":"L\u00f3pez de Frutos","year":"2026","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.110291_bb0245","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejpn.2022.07.001","article-title":"Application of the Scale for Assessment and Rating of Ataxia in toddlers","volume":"40","author":"Schouwstra","year":"2022","journal-title":"Eur. J. Paediatr. Neurol."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226005743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226005743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T19:31:41Z","timestamp":1794252701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719226005743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1096719226005743"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.110291","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A prospective, longitudinal, natural history study of neurological disease trajectory in children with late-infantile or juvenile-onset GM1 gangliosidosis or GM2 gangliosidoses: the PRONTO study","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.110291","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110291"}}